A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model

Piyush M. Vyas, Wendy J. Tomamichel, P. Melanie Pride, Clifford M. Babbey, Qiujuan Wang, Jennifer Mercier, Elizabeth M. Martin, R. Payne

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Friedreich's ataxia (FRDA) is the most common inherited human ataxia and results from a deficiency of the mitochondrial protein, frataxin (FXN), which is encoded in the nucleus. This deficiency is associated with an iron-sulfur (Fe-S) cluster enzyme deficit leading to progressive ataxia and a frequently fatal cardiomyopathy. There is no cure. To determine whether exogenous replacement of the missing FXN protein in mitochondria would repair the defect, we used the transactivator of transcription (TAT) protein transduction domain to deliver human FXN protein to mitochondria in both cultured patient cells and a severe mouse model of FRDA. A TAT-FXN fusion protein bound iron in vitro, transduced into mitochondria of FRDA deficient fibroblasts and reduced caspase-3 activation in response to an exogenous iron-oxidant stress. Injection of TAT-FXN protein into mice with a conditional loss of FXN increased their growth velocity and mean lifespan by 53% increased their mean heart rate and cardiac output, increased activity of aconitase and reversed abnormal mitochondrial proliferation and ultrastructure in heart. These results show that a cell-penetrant peptide is capable of delivering a functional mitochondrial protein in vivo to rescue a very severe disease phenotype, and present the possibility of TAT-FXN as a protein replacement therapy.

Original languageEnglish
Article numberddr554
Pages (from-to)1230-1247
Number of pages18
JournalHuman Molecular Genetics
Volume21
Issue number6
DOIs
StatePublished - Mar 2012

Fingerprint

Friedreich Ataxia
Trans-Activators
Proteins
Mitochondria
Iron
Mitochondrial Proteins
Ataxia
Aconitate Hydratase
frataxin
Cardiomyopathies
Sulfur
Oxidants
Caspase 3
Cardiac Output
Cultured Cells
Fibroblasts
Heart Rate
Phenotype
Peptides
Injections

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model. / Vyas, Piyush M.; Tomamichel, Wendy J.; Pride, P. Melanie; Babbey, Clifford M.; Wang, Qiujuan; Mercier, Jennifer; Martin, Elizabeth M.; Payne, R.

In: Human Molecular Genetics, Vol. 21, No. 6, ddr554, 03.2012, p. 1230-1247.

Research output: Contribution to journalArticle

Vyas, PM, Tomamichel, WJ, Pride, PM, Babbey, CM, Wang, Q, Mercier, J, Martin, EM & Payne, R 2012, 'A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model', Human Molecular Genetics, vol. 21, no. 6, ddr554, pp. 1230-1247. https://doi.org/10.1093/hmg/ddr554
Vyas, Piyush M. ; Tomamichel, Wendy J. ; Pride, P. Melanie ; Babbey, Clifford M. ; Wang, Qiujuan ; Mercier, Jennifer ; Martin, Elizabeth M. ; Payne, R. / A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model. In: Human Molecular Genetics. 2012 ; Vol. 21, No. 6. pp. 1230-1247.
@article{78f1363d3c514ebabc75ac7e3f67864a,
title = "A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model",
abstract = "Friedreich's ataxia (FRDA) is the most common inherited human ataxia and results from a deficiency of the mitochondrial protein, frataxin (FXN), which is encoded in the nucleus. This deficiency is associated with an iron-sulfur (Fe-S) cluster enzyme deficit leading to progressive ataxia and a frequently fatal cardiomyopathy. There is no cure. To determine whether exogenous replacement of the missing FXN protein in mitochondria would repair the defect, we used the transactivator of transcription (TAT) protein transduction domain to deliver human FXN protein to mitochondria in both cultured patient cells and a severe mouse model of FRDA. A TAT-FXN fusion protein bound iron in vitro, transduced into mitochondria of FRDA deficient fibroblasts and reduced caspase-3 activation in response to an exogenous iron-oxidant stress. Injection of TAT-FXN protein into mice with a conditional loss of FXN increased their growth velocity and mean lifespan by 53{\%} increased their mean heart rate and cardiac output, increased activity of aconitase and reversed abnormal mitochondrial proliferation and ultrastructure in heart. These results show that a cell-penetrant peptide is capable of delivering a functional mitochondrial protein in vivo to rescue a very severe disease phenotype, and present the possibility of TAT-FXN as a protein replacement therapy.",
author = "Vyas, {Piyush M.} and Tomamichel, {Wendy J.} and Pride, {P. Melanie} and Babbey, {Clifford M.} and Qiujuan Wang and Jennifer Mercier and Martin, {Elizabeth M.} and R. Payne",
year = "2012",
month = "3",
doi = "10.1093/hmg/ddr554",
language = "English",
volume = "21",
pages = "1230--1247",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model

AU - Vyas, Piyush M.

AU - Tomamichel, Wendy J.

AU - Pride, P. Melanie

AU - Babbey, Clifford M.

AU - Wang, Qiujuan

AU - Mercier, Jennifer

AU - Martin, Elizabeth M.

AU - Payne, R.

PY - 2012/3

Y1 - 2012/3

N2 - Friedreich's ataxia (FRDA) is the most common inherited human ataxia and results from a deficiency of the mitochondrial protein, frataxin (FXN), which is encoded in the nucleus. This deficiency is associated with an iron-sulfur (Fe-S) cluster enzyme deficit leading to progressive ataxia and a frequently fatal cardiomyopathy. There is no cure. To determine whether exogenous replacement of the missing FXN protein in mitochondria would repair the defect, we used the transactivator of transcription (TAT) protein transduction domain to deliver human FXN protein to mitochondria in both cultured patient cells and a severe mouse model of FRDA. A TAT-FXN fusion protein bound iron in vitro, transduced into mitochondria of FRDA deficient fibroblasts and reduced caspase-3 activation in response to an exogenous iron-oxidant stress. Injection of TAT-FXN protein into mice with a conditional loss of FXN increased their growth velocity and mean lifespan by 53% increased their mean heart rate and cardiac output, increased activity of aconitase and reversed abnormal mitochondrial proliferation and ultrastructure in heart. These results show that a cell-penetrant peptide is capable of delivering a functional mitochondrial protein in vivo to rescue a very severe disease phenotype, and present the possibility of TAT-FXN as a protein replacement therapy.

AB - Friedreich's ataxia (FRDA) is the most common inherited human ataxia and results from a deficiency of the mitochondrial protein, frataxin (FXN), which is encoded in the nucleus. This deficiency is associated with an iron-sulfur (Fe-S) cluster enzyme deficit leading to progressive ataxia and a frequently fatal cardiomyopathy. There is no cure. To determine whether exogenous replacement of the missing FXN protein in mitochondria would repair the defect, we used the transactivator of transcription (TAT) protein transduction domain to deliver human FXN protein to mitochondria in both cultured patient cells and a severe mouse model of FRDA. A TAT-FXN fusion protein bound iron in vitro, transduced into mitochondria of FRDA deficient fibroblasts and reduced caspase-3 activation in response to an exogenous iron-oxidant stress. Injection of TAT-FXN protein into mice with a conditional loss of FXN increased their growth velocity and mean lifespan by 53% increased their mean heart rate and cardiac output, increased activity of aconitase and reversed abnormal mitochondrial proliferation and ultrastructure in heart. These results show that a cell-penetrant peptide is capable of delivering a functional mitochondrial protein in vivo to rescue a very severe disease phenotype, and present the possibility of TAT-FXN as a protein replacement therapy.

UR - http://www.scopus.com/inward/record.url?scp=84863278400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863278400&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddr554

DO - 10.1093/hmg/ddr554

M3 - Article

C2 - 22113996

AN - SCOPUS:84863278400

VL - 21

SP - 1230

EP - 1247

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 6

M1 - ddr554

ER -